Enterofuril capsules 100mg, No. 30

Common to all dosage forms

diarrhea of ??bacterial origin.

For oral suspension additionally

chronic lesions of the gastrointestinal tract of bacterial etiology, accompanied by dyspeptic symptoms.

Inside. Nifuroxazide therapy should not be continued for more than 7 days.

100 mg capsules

For adults and children over 7 years of age, the drug is prescribed for 2 caps. (200 mg) 4 times a day, the daily dose is 800 mg.

For children 3Ц7 years old, the drug is prescribed for 2 caps. (200 mg) 3 times a day, the daily dose is 600 mg.

200 mg capsules

For adults and children over 7 years of age, the drug is prescribed 1 capsule. (200 mg) 4 times a day, the daily dose is 800 mg.

For children 3Ц7 years old, the drug is prescribed 1 caps. (200 mg) 3 times a day, the daily dose is 600 mg.

Oral suspension

For dosing, a dosage spoon of 5 ml is used, having a graduation of 2.5 ml.

Shake the suspension well before use.

Children 1-6 months: 2.5 ml 2-3 times a day (with an interval of 8 to 12 hours).

Children 7 months - 2 years: 2.5 ml 4 times a day (with an interval of 8 hours).

Children 3-7 years old: 5 ml 3 times a day (with an interval of 8 hours).

Adults and children over 7 years old: 5 ml 3-4 times a day (with an interval of 6-8 hours).

1 capsule contains:
Active ingredients: nifuroxazide 100.0 / 200.0 mg
Excipients: sucrose 36.00 / 71.00 mg, corn starch 44.00 / 68.00 mg, microcrystalline cellulose 5.10 / 9.0 mg , magnesium stearate 0.19 / 2.0 mg.
The composition of the capsule (100mg): gelatin, titanium dioxide, quinoline yellow dye, azorubin dye, crimson dye [Ponso 4R];
The composition of the capsule (200mg): gelatin, titanium dioxide, iron oxide yellow dye.

• Hypersensitivity to nitrofuran derivatives or other components of the drug;

• Children under 3 years of age (for this dosage form).

• Fructose intolerance, glucose-galactose malabsorption syndrome, sucrase and isomaltase deficiency.

Trade name of the drug:

EnterofurilЃ

International non-proprietary name:

nifuroxazide

Dosage form:

capsules

Composition:

1 capsule contains:
Active ingredients: nifuroxazide 100.0 / 200.0 mg
Excipients: sucrose 36.00 / 71.00 mg, corn starch 44.00 / 68.00 mg, microcrystalline cellulose 5.10 / 9.0 mg , magnesium stearate 0.19 / 2.0 mg.
The composition of the capsule (100mg): gelatin, titanium dioxide, quinoline yellow dye, azorubin dye, crimson dye [Ponso 4R];
The composition of the capsule (200mg): gelatin, titanium dioxide, iron oxide yellow dye.

Description:

Hard gelatin opaque yellow capsules No. 2 (100 mg capsules) and No. 0 (200 mg capsules), filled with yellow powder, or yellow powder with inclusions in the form of small pieces of compressed mass, or compressed yellow powder, which crumbles when light pressed.

Pharmacotherapeutic group:

Antimicrobial agent, nitrofuran.

ATX code: A07AX03

Pharmacological properties

Pharmacodynamics
Broad-spectrum antimicrobial agent, 5-nitrofuran derivative.
It is assumed that the antimicrobial activity of nifuroxazide is caused by the presence of an NO2-group in its composition, which inhibits the activity of dehydrogenase and disrupts protein synthesis in pathogenic bacteria.
It is active against gram-positive microorganisms (Streptococcus aureus, Staphylococcus pyogenes, Clostridium), gram-negative enterobacteria (Escherihia coli, Salmonella spp., Shigella spp., Klebsiella spp., Enterobacter spp., Vibriococteri spp., Vibrio Campyella cholera, ...
Nifuroxazide has no effect on saprophytic flora, does not disturb the balance of normal intestinal flora. In case of acute bacterial diarrhea, it restores intestinal eubiosis. When infected with enterotropic viruses, it prevents the development of bacterial superinfection.

Pharmacokinetics
After oral administration, nifuroxazide is practically not absorbed from the digestive tract, and exerts its antibacterial effect exclusively in the intestinal lumen. Completely excreted through the gastrointestinal tract. The rate of elimination depends on both the dose of the drug and the motility of the intestinal tract.

Indications for use

Diarrhea of ??bacterial origin;

Contraindications

• Hypersensitivity to nitrofuran derivatives or other components of the drug;

• Children under 3 years of age (for this dosage form).

• Fructose intolerance, glucose-galactose malabsorption syndrome, sucrase and isomaltase deficiency.

Application during pregnancy and lactation

The use of EnterofurilЃ during pregnancy is possible only in cases where the expected benefit of therapy to the mother outweighs the potential risk to the fetus.
EnterofurilЃ is not absorbed from the gastrointestinal tract and does not enter the systemic circulation, however, the use of the drug during lactation is possible only for strict indications, and the issue of stopping breastfeeding should be resolved.

Method of administration and dosage

It is used internally.
Capsules 100 mg:
Adults and children over 7 years old: 2 capsules x 4 times a day (200 mg x 4 times a day, total 800 mg of nifuroxazide / day)
Children 3-7 years old: 2 capsules x 3 times a day ( 200 mg x 3 times a day, total 600 mg nifuroxazide / day)
200 mg capsules:
Adults and children over 7 years old: 1 capsule x 4 times a day (total 800 mg nifuroxazide / day)
Children 3-7 years old: 1 each capsule x 3 times a day (200 mg x 3 times a day, total 600 mg of nifuroxazide / day) Nifuroxazide therapy should not be continued for more than 7 days.

Side effect

Nausea, vomiting, allergic reactions (rash, urticaria, Quincke's edema, anaphylactic shock).

Overdose

The drug is not absorbed from the gastrointestinal tract and does not enter the systemic circulation. Overdose symptoms are unknown. If the dose is exceeded, gastric lavage and symptomatic treatment are recommended.

Interaction with other medicinal products

There is no evidence that nifuroxazide interacts with other drugs.

special instructions

When treating diarrhea concomitantly with nifuroxazide therapy, it is necessary to carry out rehydration therapy (oral or intravenous) in accordance with the patient's condition and the intensity of the diarrhea.
During therapy, the use of alcohol is prohibited, as it increases the body's sensitivity to nifuroxazide.
If symptoms of hypersensitivity (shortness of breath, rash, itching) appear, the drug should be discontinued.

Influence on the ability to drive vehicles and work with mechanisms

The drug does not affect psychomotor activity, the ability to drive vehicles and work with mechanisms.

Release form

Capsules.
Dosage 100 mg
10 capsules in a blister made of PVC film and aluminum foil. 3 blisters with instructions for use are placed in a cardboard box.
Dosage 200 mg
8 capsules in a blister made of PVC film and aluminum foil. 2 or 4 blisters with instructions for use are placed in a cardboard box.

Storage conditions

At a temperature not higher than 30 ? C.
Keep out of the reach of children.

Shelf life

5 years.
Do not use after the expiration date.

Conditions of dispensing from pharmacies

Dispensed without a doctor's prescription.